The earnings call was largely positive, with strong data for REZPEG in atopic dermatitis and a solid financial position enabling future clinical advancements. The company is actively preparing for Phase III trials and expanding its market potential. However, challenges such as net losses, injection site reactions, and ongoing litigation with Lilly were noted.

Company Guidance

During the Nektar Therapeutics Second Quarter 2025 Financial Results Conference Call, significant guidance and updates on various metrics were provided. The company highlighted transformative progress in its lead clinical program, rezpegaldesleukin (REZPEG), reporting compelling initial data in atopic dermatitis, with plans to advance into Phase III development in 2026. The market for atopic dermatitis has grown to $15 billion in U.S. sales, with expectations to reach $30 billion by 2033. Nektar's recent $115 million equity financing strengthened its financial position, extending the cash runway into 2027. The REZOLVE-AD study, involving 393 patients, met its primary endpoints, including statistical significance for mean percent change in EASI score from baseline and other key metrics like EASI-75 and BSA. The company plans to report additional data in Q1 2026 and is actively preparing for end-of-Phase II meetings with the FDA. Financially, Nektar ended the second quarter with $175.9 million in cash and investments, projecting a year-end balance between $180 million and $185 million. R&D expenses are expected to range between $125 million and $130 million for the full year, with G&A expenses projected between $70 million and $75 million.

Positive Data for REZPEG in Atopic Dermatitis

Reported compelling initial data for rezpegaldesleukin (REZPEG) in atopic dermatitis, establishing it as a potential first-in-class novel T regulatory mechanism for patients.

FDA Fast Track Designation

Granted FDA Fast Track designation for REZPEG in both atopic dermatitis and alopecia areata, allowing for expedited regulatory pathways.

Strong Financial Position

Completed an oversubscribed $115 million equity financing, extending cash runway into 2027.

Phase III Readiness

Initiated Phase III readiness activities for REZPEG, with plans to start Phase III studies in the first half of 2026.

Market Potential

The atopic dermatitis market is expected to grow significantly, with opportunities for REZPEG in both biologic naive and experienced patients.

Nektar Therapeutics (NKTR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NKTR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-2.79 / -	-2.7	―	―	―
Aug 07, 2025	2025 (Q2)	-3.03 / -2.95	-3.75	21.33% (+0.80)	―
May 08, 2025	2025 (Q1)	-2.56 / -3.60	-2.85	-26.32% (-0.75)	―
Mar 12, 2025	2024 (Q4)	-2.03 / 0.45	-3.3	113.64% (+3.75)	―
Nov 07, 2024	2024 (Q3)	-2.98 / -2.70	-3.6	25.00% (+0.90)	―
Aug 08, 2024	2024 (Q2)	-2.77 / -3.75	-4.05	7.41% (+0.30)	―
May 09, 2024	2024 (Q1)	-2.85 / -2.85	-10.95	73.97% (+8.10)	―
Mar 04, 2024	2023 (Q4)	-3.16 / -3.30	-4.8	31.25% (+1.50)	―
Nov 07, 2023	2023 (Q3)	-2.98 / -3.60	-4.65	22.58% (+1.05)	―
Aug 08, 2023	2023 (Q2)	-4.22 / -4.05	-12.75	68.24% (+8.70)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NKTR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$21.75	$23.06	+6.02%
May 08, 2025	$9.28	$8.83	-4.85%
Mar 12, 2025	$12.30	$12.23	-0.57%
Nov 07, 2024	$20.55	$21.00	+2.19%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Nektar Therapeutics (NKTR) report earnings?

Nektar Therapeutics (NKTR) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Nektar Therapeutics (NKTR) earnings time?

Nektar Therapeutics (NKTR) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NKTR EPS forecast?

NKTR EPS forecast for the fiscal quarter 2025 (Q3) is -2.79.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing